It has been shown that by selectively binding PPARα receptors, PEA is able to down‐regulate iNOS expression and nuclear factor‐κB (NFκB) activation, and in turn the inflammation in a number of chronic inflammatory conditions, including experimental and human models of inflammatory bowel disease (IBD) 49, 50, 51. The gene discussed is NFKB1; the disease is inflammatory bowel disease.